Recently, we described a new biological function of p53 in inhibiting recombination processes when encountering mismatches in heteroduplexes (DudenhoÈ er et al., 1998) . Here, we characterized protein domains of p53 participating in this process by in vitro analysis of mutated p53 proteins, and by applying our SV40-based assay system on monkey cells, which express dierent p53 variants. We present evidence that both binding of arti®cial recombination intermediates and p53-dependent recombination control require an intact p53 core and the oligomerization domain, strongly suggesting that the recognition of DNA undergoing recombination represents an essential step of this genomic surveillance mechanism. Further analyses indicated a role of the C-terminus in negatively regulating recombination control, an eect which can be neutralized by concurrent mismatch recognition. p53 lacking the oligomerization domain totally lost its ability to suppress homologous recombination. The cancer-related mutant p53(273H) was also signi®cantly defective in this function, although we observed only twofold reductions in the corresponding transactivation activities on p53-response elements in episomal constructs. HDM2, an inhibitor of p53's transcriptional and growth regulatory activities, interfered with the inhibition of DNA exchange processes by p53 only weakly. Thus, functions of p53 in recombination control can be structurally dissociated from p53-dependent transcriptional transactivation.
Introduction
Inactivation of wild-type p53 represents a key step during tumor progression, which has been causally linked to its function in maintaining genomic integrity (Livingstone et al., 1992; Yin et al., 1992; Carder et al., 1993; Harvey et al., 1993) . In response to DNA damaging treatments latent p53 becomes activated (Siegel et al., 1995; Lutzker and Levine, 1996) to induce cell cycle arrest or apoptosis in order to prevent the proliferation of genetically damaged cells (for review see Jacks and Weinberg, 1996) . Arrest at the G1/S border is dependent on transcriptional upregulation of the waf1 gene encoding p21, which inhibits cell cycle progression by interactions with cyclin dependent kinases (cdk) (El-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993) . A newly discovered target gene of p53 executing G2 arrest is 14-3-3s, which inactivates the signaling pathway towards cdk1 by sequestering Cdc25C (Hermeking et al., 1997) . Transcriptional transactivation by p53 is neutralized by tight binding of the MDM2 (mouse double minute 2) protein to residues 17 ± 27 within the acidic domain, thereby masking this region from interactions with the basal transcription factors TBP, TAF31 and TAF70 (for review see Prives, 1998) . The mdm2 gene itself also represents a transcriptional target of p53, which in eect creates a negative feedback loop.
Sequence speci®c DNA recognition by p53 requires the intact core domain Cho et al., 1994) , where the tumorigenic mutations cluster (Hollstein et al., 1991) . Noticeably, the central region encompassing amino acids 83 ± 323 within human p53 is necessary and sucient for exerting its intrinsic 3'?5' exonuclease activity on DNA in a nonsequence speci®c fashion (Mummenbrauer et al., 1996; Janus et al., 1996) . The region spanning amino acids 323 ± 355 is responsible for stable tetramerization via leucine zipper-like motifs Waterman et al., 1995) . The C-terminus (amino acids 320 ± 393) of p53 also contacts the subunits XPB and XPD of the dual transcription/excision repair factor TFIIH (Leveillard et al., 1996) . Other cellular binding partners of p53, which also suggest a role of p53 in repair processes, are Cockayne syndrome B protein (CSB), a helicase involved in coupling transcription to repair , topoisomerase I involved in transcription, replication, repair, and recombination (Albor et al., 1998) , and replication protein A (RPA), a single-stranded DNA binding protein complex with functions in replication, repair and recombination (reviewed in Wold, 1997) . The C-terminal 30 amino acids play a crucial role in the recognition of several DNA structures related to DNA damage (dsDNA ends, ssDNA, insertion/deletion mismatches) and are essential for RNA and DNA reannealing activities (Oberosler et al., 1993; Brain and Jenkins, 1994; Bakalkin et al., 1994; Jayaraman and Prives, 1995; Lee et al., 1997; Reed et al., 1995; Wu et al., 1995) . In its native state, this region negatively controls sequence-speci®c DNA binding of the core, but interactions with co-factors, DNA damage binding, and post-translational modi®cations can neutralize this eect (Jayaraman and Prives, 1995; Lee et al., 1995; Bayle et al., 1995; Reed et al., 1995; Selivanova et al., 1996; Hupp et al., 1992) . p53 lacking the C-terminus is constitutively active for transactivating transcription, a situation resulting in vivo in a species-and tissuespeci®c manner from alternate splicing (Wolf et al., 1985; Kulesz-Martin et al., 1994) , or by autoproteolytic cleavage after sensing damaged DNA (Okorokov et al., 1997) .
Recombination represents the ®nal and irreplaceable repair mechanism under circumstances when DNA double-strand breaks or gaps appear. However, uncontrolled recombination events are a source of detrimental rearrangements, such as gene ampli®cation events or unequal sister chromatid exchanges. Homologous recombination appears to be essential during the normal development of mammalian organisms, as can be deducted from the embryonic lethal phenotype of both rad51 nullizygotes (Lim and Hasty, 1996; Tsuzuki et al., 1996) , and of BRCA17/7 mice, lacking the tumor suppressor BRCA1 (Hakem et al., 1997; Ludwig et al., 1997) , a complex partner of Rad51 (Scully et al., 1997) . Survival of the embryos in both knockouts can be prolonged by concomitant knockout of p53, indicating genetic interactions between p53 and Rad51, as well as between p53 and BRCA1 in addition to physical interactions described before (StuÈ rzbecher et al., 1996; Ouchi et al., 1998; Zhang et al., 1998) . Previous work has demonstrated that p53 inhibits homologous DNA exchanges in mitotically growing cells (WiesmuÈ ller et al., 1996; Bertrand et al., 1997; Mekeel et al., 1997) . Recently, we have provided insight into the underlying mechanism by observing a tight correlation between junction DNA binding by p53 in vitro and negative regulation of recombination in living cells, when certain mispairings appear in recombination intermediates (DudenhoÈ er et al., 1998) . In this work, we have analysed the structure-function relationships of this recombination control mechanism, allowing us to draw conclusions on the biochemical activities of p53 involved and on the relationships to other biological functions of p53.
Results

Expression of modi®ed p53her proteins in LLC-MK 2 monkey cells
To analyse the role of p53 domains possibly involved in recombination regulation, cells stably expressing deletion or point mutants of p53 were established by use of a conditional system. p53 C-terminally fused to the human estrogen receptor hormone-binding domain (p53her), closely resembles bona ®de wild-type p53 and can be activated in a b-estradiol-dependent fashion (Roemer and Friedman, 1993; DudenhoÈ er et al., 1998) . Proteins were ectopically expressed in LLC-MK 2 monkey cells, because these cells allow the quantification of DNA-exchange processes between two SV40-virus genomes dierentially point-mutated to create mismatches in heteroduplexes. Endogenous p53 in LLC-MK 2 cells lacks amino acids 237 ± 239 (p53D237 ± 239), which causes a conformational change towards PAb240 reactivity (von der Weth and Deppert, 1993) and a loss of function with respect to recombination modulating activities (WiesmuÈ ller et al., 1996; DudenhoÈ er et al., 1998) . To identify a conceivable link between regulation of recombination processes and exonucleolytic degradation of DNA, we sought to stably express the her-chimera p53(273H)her, which has lost 3'?5' exonuclease activity (Mummenbrauer et al., 1996) , but still performs sequence-speci®c DNA-binding (Bargonetti et al., 1993; Prasad and Church, 1997; Park et al., 1994) . To investigate the role of DNA damage recognition, DNA-reannealing, and oligomerization in recombination control exerted by p53, we constructed plasmids pSV53(1 ± 363)her and pSV53(1 ± 333)her. After co-transfection of phyg with either pSVp53(273H)her, pSVp53(1 ± 363)her, or pSV53(1 ± 333)her, we compared the steady state levels of p53her protein in hygromycin resistant clones after Western blotting (Figure 1a and b) . Quantitative analyses for maximally expressing clones of each cell type showed that p53(1 ± 363)her expression was 1.4-fold above wild-type p53her in LLC-MK 2 (p53her)-17 cells for clone LLC-MK 2 [p53(1 ± 363)her]-6. p53(273H) her from clone 8 was detected equally well as the wildtype p53her control. Protein expression for the LLC-MK 2 [p53(1 ± 333)her]-12 clone was found to be more than sevenfold reduced.
To make sure that p53(1 ± 333)her protein, having retained only the major localization signal at amino acids 316 ± 325 (Shaulsky et al., 1990) , was targeted to the nucleus, we sequentially extracted nuclear proteins. As can be detected from the autoradiographs in Figure  1c , p53her, p53(1 ± 363)her, the endogenous mutant p53D237 ± 239, and, importantly, p53(1 ± 333)her were present in the cytosolic/nucleosolic fraction A and dissociated from nuclear structures by extraction with up to 200 mM at pH 9.0 (fractions B and C).
Transcriptional transactivation via a p53-speci®c sequence element
To decide whether the manipulation of the p53 status in the newly established transgenic clones was re¯ected in changes in the biological properties, such as transcriptional transactivation, we measured chloramphenicol acetyltransferase levels in transient transfection assays with a CAT-reporter construct containing 13 copies of the p53-speci®c motif found in the human ribosomal gene cluster (Kern et al., 1992) . While transactivation was low in the absence of estradiol for all cell types tested (Figure 2 ), increased CATproduction with the inducing agent indicated activation of the exogenous p53her variants. These results also unequivocally demonstrated that the endogenous mutant p53D237 ± 239, was unable to exert a dominant negative eect on the inducible fusion proteins. While p53her promoted CAT expression was ninefold higher than the basal level of the LLC-MK 2 (neo) control cells, the ratio for LLC-MK 2 [p53(1 ± 363)her] extracts was 21. This ®nding for the her-chimera was compatible with the C-terminal 30 amino acids of p53 having a negative regulatory role in sequence-speci®c DNAbinding Jayaraman and Prives, 1995) . In agreement with the postulated synergism between p53 oligomerization and transcriptional transactivation , mutant p53(1 ± 333)her lacking the tetramerization domain performed intermediary transactivation, fourfold above the control. The her-chimera containing the DNA contact mutant p53(273H) (Cho et al., 1994) directed the accumulation of CAT enzyme at a ratio of ®ve times above the basal values corresponding to a less than twofold reduction of the wild-type p53 activity. 
Control of recombination processes in the transgenic p53her cell lines
For structure-function analyses of recombination control we measured genetic exchange rates between viral genomes after SV40-tsVP1(196Y) and SV40- Figure 1 Western blot analyses of LLC-MK 2 cell lines expressing dierent p53her mutants. To determine the steady-state levels and the cellular distribution of ectopically expressed p53her variants, proteins were separated in 10% SDS-polyacrylamide gels and transferred onto PVDF membranes. p53 fusion proteins were detected by use of the primary antibody DO-1 (Vojtesek et al., 1992) , the secondary peroxidase-conjugated anti-mouse IgG (BioRad), and chemiluminescent enhancement. In ( tsVP1(290T) co-infections, yielding the most dramatic inhibitory eect by wtp53, which correlates with p53's ability to preferentially recognize A-G and C-T mismatches on heteroduplexes (DudenhoÈ er et al., 1998) . From this set of recombination experiments summarized in Table 2 , it became clear that, under estradiol-inducing conditions, full-length p53her suppressed homologous exchange processes by more than one order of magnitude (126), but the p53 version truncated by 30 amino acids at its C-terminus displayed even higher inhibition (146). In contrast, the highest exchange rates between viral genomes were obtained with LLC-MK 2 [p53(1 ± 333)her] cells. This cannot be explained by dierences in protein levels, as LLC-MK 2 (p53her)-32 cells, which like LLC-MK 2 [p53(1 ± 333)her]-12 express 1/7 of fusion protein as compared to LLC-MK 2 (p53her)-17, signi®cantly suppress recombination rates (data not shown). In LLC-MK 2 [p53(273H)her]-8 mutant cells with protein expression levels comparable to LLC-MK 2 (p53her)-17, recombination events were prevented only weakly (36).
Recognition of 3-stranded junctions by p53 mutants
Recently, we observed that the level of inhibition of homologous recombination and the strength of Figure 2 Transcriptional activities of p53her fusion proteins. Cells were transfected with plasmid pG13-CAT (Kern et al., 1992) and split cultures treated with the inducing agent b-estradiol. Chloramphenicol acetyltransferase levels (CAT/mg protein) in total extracts were quanti®ed colorimetrically from 2 ± 3 independent measurements. Data illustrated diagrammatically are the mean values and standard deviations calculated for clones LLC-MK 2 (neo)-a and LLC-MK 2 (hygro)-1, LLC-MK 2 (p53her)-17, LLC-MK 2 [p53(273H)her]-8 and -10, LLC-MK 2 [p53(1 ± 363)her]-6 and -7, LLC-MK 2 [p53(1 ± 333)her]-12, LMV6, and LMV(HDM2/ p53her)-3 clones -8, -10, -11 (n=8) , for the control LMV-clone LMV6 from four independent measurements, and for LMV-(HDM2/p53her) with clones -2, -3 (n=5) binding of arti®cial recombination intermediates of full-length wild-type p53 correlated with respect to the mismatch types involved (DudenhoÈ er et al., 1998) . Consequently, we performed in vitro-binding assays for dierent p53 mutant proteins overexpressed in insect cells with radioactively labeled 3-stranded junction DNAs. Wild-type human protein, either PAb421-immunopuri®ed or enriched from nuclear extracts, bound to 3-stranded intermediates even at concentrations as low as 1 nM. In contrast, fractions with oncogenic p53 variants at a ®nal concentration of 5 nM containing either p53(248P), a DNA-contact mutant, or p53(273P), reactive towards the antibody PAb240 speci®c for the mutant p53 conformation (Ory et al., 1994) , were unable to produce a gel shift (Figure 3a) . Next, we talon-puri®ed murine p53 proteins truncated at the N-terminus by 79 amino acids [p53(80 ± 390)], or at the C-terminus by 30 [p53(1 ± 360)] or by 70 amino acids [p53(1 ± 320)] and compared them to the fulllength version in EMSAs. p53(80 ± 390), applied at increasing protein concentrations, was able to stably bind junction DNAs (Figure 3b ), although at reduced anities and accompanied by a weakened capacity to form tetrameric complexes on DNA. Strikingly, p53(1 ± 320) had completely lost the ability to recognize these 3-stranded DNA-structures at concentrations, at which wild-type p53 tetramers and octamers fully titrated out the substrate, and at which also p53(1 ± 360) performed strong binding (see Figure  3c ). For a more detailed analysis of p53(1 ± 360), which is devoid of the amino acid stretch implicated in DNA damage recognition (Jayaraman and Prives, 1995; Lee et al., 1995; Reed et al., 1995) , we titrated DNA substrates for anity measurements with 3-stranded junctions containing perfectly matching doublestranded termini versus junctions comprising an A-G mismatch. Intriguingly, the deletion of the C-terminal 30 amino acids resulted in practically identical K Dvalues for both substrates (Table 3) , whereas wild-type p53 displays comparable high-anity binding only with the speci®c mismatch substrate (DudenhoÈ er et al., 1998).
Co-expression of HDM2 and p53her in LLC-MK 2 cells
We wanted to check if a general antagonist of p53's transcriptional, growth suppressing and apoptotic activities, namely HDM2 (for review see Prives, 1998) , would also modulate p53's regulatory function during DNA exchange processes. Due to the growthinhibitory eects of HDM2 overexpression (see Materials and methods and Brown et al., 1998), we decided to employ the conditional expression system relying on the b-estradiol-inducibility of GalER-VP16, a Gal4-derived transcription factor (Braselmann et al., 1993) , which oers full compatibility for concomitant p53her expression. GalER-VP16 producing LLC-MK 2 clones (LMV) were established and co-transfected with pSV53her, phyg, and the Gal4-target pGC-HDM2. As expected from the strategy used for HDM2 expression via estradiol-inducible de novo synthesis, co-expression positive LMV(HDM2/p53her) clones -2, -3, and -7, showed an average of eightfold higher HDM2 protein amounts after estradiol-treatment (Figure 4a ). This HDM2 increase could not be attributed to the transcriptional activities of estradiol-activated p53her on the endogenous monkey MDM2 gene, because threefold lower levels of monkey MDM2 were produced in LLC-MK 2 (p53her)-17 cells after induction (Figure 4a ). When we checked the two ectopically expressed proteins for functional interactions by looking for p53her co-immunoprecipitation with anti-MDM2 serum, complex formation between p53her and HDM2 was clearly demonstrated for clones 2 and 3, and to a lesser degree for clone 7 (Figure 4b) . In transient transfection assays with LMV(HDM2/ p53her)-2 and -3 cells, we observed wtp53her-dependent CAT production of only two to three times that measured for the parental LMV6 cells after estradiol-treatment (Figure 2) . Correspondingly, coexpression of HDM2 and p53her did not result in a pronounced estradiol-inducibility of growth retardation (Table 1) . This indicates that, in the presence of elevated HDM2 levels, p53her could not fully develop its growth suppressing function. However, in clones coexpressing the transactivation-antagonist HDM2, p53her still had the potential to lower DNA exchange rates down to 1.5 times the value measured for LLC-MK 2 (p53her) cells.
Discussion
In this work, we have looked for structural properties of the p53 molecule, which are essential for the inhibitory eects on homologous recombination processes (DudenhoÈ er et al., 1998) . Similarities to the structural prerequisites for sequence-speci®c transactivation became apparent. More importantly, functions of p53 in transcription, in the control of growth, and in the inhibition of DNA exchange processes could be dissected by the analysis of appropriate p53 mutant and HDM2 expressing cell lines.
Structural characteristics of the regulation of recombination processes by p53 and their implications for the biochemical mechanism Recognition of recombination intermediates versus consensus sequences In agreement with data from Lee et al. (1997) , we have provided evidence for tight interactions of p53 with arti®cial recombination intermediates comprising¯exible junctions (DudenhoÈ er et al., 1998). Sequence speci®c DNA binding by p53 also requires a certain¯exibility or secondary structures on the target DNAs and seems to be accompanied by conformational changes of p53 (Nagaich et al., 1997; Balagurumoorthy et al., 1995; Stenger et al., 1992; Kim et al., 1997) . Therefore, we studied, whether these similarities between the two types of DNA interactions are re¯ected by the structural requirements on the p53 molecule. Indeed, we observed that tumorigenic p53 proteins with amino acid exchanges located within the central region, namely the human DNA contact mutant p53(248P) and the conformational mutant p53(273P), which have lost the capability to bind DNA in a sequence-speci®c manner (Ory et al., 1994) , do not recognize recombination intermediates as well. We also did not observe any suppression of imprecise DNA exchange processes in the presence of abundantly expressed p53D237 ± 239 with altered conformation (von der Weth and Deppert, (273), and mutant p53(248P) protein (248) were enriched from nuclear extracts and analysed at protein concentrations of 5 nM (calculated for the tetramer). (b) Histidine-tagged p53 proteins from murine origin were expressed in insect cells and puri®ed via talon metal anity chromatography. Wild-type p53 (wt) was applied to the binding mixtures at concentrations of 8 nM, and 17 nM, p53 (80 ± 390) at concentrations of 8, 17, 33 and 50 nM. (c) Histidinetagged murine wild-type p53 (wt) was added at 140 and 14 nM, respectively, p53(1 ± 360) and p53(1 ± 320) at 14 and 7 nM 1993), and measured signi®cantly reduced recombination control activities in cells expressing the DNA contact mutant p53(273H)her. These results implicate the importance of the conformational integrity within the core and of residues directly contacting the DNA (Cho et al., 1994) for both secondary structure speci®c DNA interactions and the potential of p53 to suppress imprecise recombination.
p53 binds consensus sites most strongly within dimers and tetramers (Waterman et al., 1995) , but even with the isolated core domain of p53, lacking the helical oligomerization domain, cooperative binding and oligomer stacking at p53-response-elements can be detected Balagurumoorthy et al., 1995) . In this study, a dependence on the presence of the tetramerization domain became apparent for binding to 3-stranded junctions in vitro. Re¯ecting these binding data, p53(1 ± 333)her expressed in monkey cells failed to inhibit DNA exchanges. This strict correlation supported our idea that the recognition of recombination intermediates by p53 is integral to the recombination control mechanism, just as sequence-speci®c DNA binding represents the ®rst step in transcriptional transactivation.
Aside from the importance of the quarternary structure of p53, it is also conceivable that heterologous protein-protein interactions involving the oligomerization domain modulate the recognition of DNA junctions or are needed to execute the blockage in the DNA exchange process. One candidate for interactions is the Cdk7/Cyclin H/p36 subunit (CAK) of the TFIIH-holoenzyme (Schneider et al., 1998) , a newly discovered kinase activating p53 by DNA damage induced phosphorylation (Lu et al., 1997; Ko et al., 1997) . Furthermore, the last 73 amino acids of p53 seem to be important to recruit and modulate the activities of the subunits XPB and XPD of the dual nucleotide excision repair and transcription factor TFIIH (Leveillard et al., 1996) . Although wild-type and mutant p53 proteins bind to XPB and XPD, the helicase activities are inhibited by wild-type p53, but not by conformation mutants, and less eciently by DNA contact mutants (Leveillard et al., 1996; Wang et al., 1995) . In view of our data demonstrating for the conformation mutant p53D237 ± 239 the loss of and for the DNA contact mutant p53(273H) the defectiveness in recombination inhibition, these helicase interactions could be envisioned to be of functional signi®cance in recombination control. Most interestingly, the hRad51 complex partner BRCA1 interacts with p53 between amino acids 300 ± 393 (Ouchi et al., 1998; Zhang et al., 1998) . BRCA1 can be imagined to stabilize functional interactions between p53 and hRad51. Figure 4 Western blot analyses of cell lines co-expressing HDM2 and p53her. HDM2 expression levels and HDM2-p53 protein interactions in LMV(HDM2/p53her) clones -2, -3 and -7 were studied after cultivation in the presence (+) or absence (7) of 2 mM b-estradiol for 4 h. HDM2 was precipitated by a polyclonal serum from guinea pig speci®c for MDM2 and precipitates were subjected to Western analyses. The positions of HDM2 and p53her, are indicated. (a) HDM2 from extracts containing 25 mg of total proteins was detected in Western blots by the monoclonal antibody 2A10 (Hall et al., 1997) coupled to peroxidaseconjugated anti-mouse IgG (BioRad) and the ECL procedure. (b) p53her co-precipitated from extracts with 95 mg of total proteins was detected on Western blots by polyclonal sheep-serum directed to human p53 (Boehringer Mannheim) and anitypuri®ed peroxidase-conjugated goat anti-sheep IgG (Sigma)
Activation of recombination inhibition by mismatch recognition
Cells expressing the C-terminal deletion mutant p53(1 ± 363)her in LLC-MK 2 cells showed maximally, namely 14-fold, reduced spontaneous recombination rates. These data indicated that biochemical functions of p53 attributed to the C-terminal 30 amino acids are unlikely candidates for the mechanism underlying the suppression of recombination events. Consequently, neither binding or reannealing of single-stranded DNA ends within recombination intermediates (Oberosler et al., 1993; Brain and Jenkins, 1994; Bakalkin et al., 1994) nor recognition of DNA damage (Jayaraman and Prives, 1995; Lee et al., 1995; Reed et al., 1995; Wu et al., 1995) seemed to be essential for this process. However, we were able to attribute the recognition of speci®c mismatches on recombination intermediates to this short domain of p53. Mismatch recognition alleviates negative regulation, as deletion of the C-terminus liberated the full potential to bind arti®cial recombination intermediates independent of the presence of mispairings. To prove constitutive activation of p53(1 ± 360) not only in 3-stranded junction DNA binding but also in recombination suppression, we designed assays with the virus combination SV40-tsVP1(196Y) and SV40-tsVP1 (286S)-C2354T, to provoke heteroduplex formation encompassing single G-T or A-C mismatches, which do not stimulate binding of wild-type p53 to 3-stranded junctions (DudenhoÈ er et al., 1998) . As would be predicted from our in vitro data, LLC-MK 2 [p53(1 ± 363)her] cells tested with this virus combination displayed a reduction by more than a factor of 10 compared to a ®vefold recombination suppression in LLC-MK 2 (p53her) cells. These observations supported the idea that full-length p53 is part of a surveillance mechanism directed predominantly towards imprecise recombination events. From the constitutive activation of C-terminally truncated p53 in suppressing spontaneous recombination processes, a biological role might be envisioned for p53as, the murine splice variant lacking the C-terminal 17 amino acids, which appears during the cell-cycle phase G2 (Kulesz-Martin et al., 1994) , when genomic surveillance mechanisms are particularly important to avoid unequal sister chromatid exchanges.
Possible role of the exonuclease activity
Our mapping data might be interpreted to exclude a major contribution of p53's exonuclease activity in controlling recombination, as the same C-terminal truncation in p53(1 ± 333), which causes the loss of recombination control, results in a stimulation of exonucleolytic degradation by more than one order of magnitude (Janus et al., 1999) . We noticed slightly elevated recombination rates for LLC-MK 2 [p53(1 ± 333)her] cells, which might be the consequence of unrestrained nucleolytic processing by p53(1 ± 333)her. From this, core fragments of p53 autoproteolytically generated in response to DNA damage (Okorokov et al., 1997) would not be expected to play a role in the suppression of recombination processes. However, like p53(1 ± 333), p53(1 ± 363) performs elevated exonuclease activity, but represses recombination maximally. These seemingly paradoxical ®ndings might indicate that C-terminal regions missing in p53(1 ± 333) are essential for targeting the exonuclease domain to its proper DNA substrate or into the proximity of essential protein partners with respect to this surveillance mechanism. Indeed, in support of the idea that p53's nuclease activity within the context of the core and oligomerization domain might play an unknown role, we found exonuclease negative p53(273H) (Mummenbrauer et al., 1996) to be signi®cantly defective in recombination control.
In conclusion, the structural prerequisites on p53 to monitor genetic exchange processes in direct contact with the DNA are the integrity of the core and the Figure 5 p53-dependent cellular activities in response to changes in the p53 status Activities of p53 contributing to recombination control C Dudenho Èffer et al tetramerization domain, whereas the C-terminus modulates this activity in response to the degree of sequence divergences detected on newly formed heteroduplexes, thereby providing ®delity control.
Transcriptional transactivation and the regulation of recombination processes are related but distinct functions of p53
The concept that p53-mediated upregulation of the cellcycle regulatory gene waf1 is essential to prevent spontaneous tumorigenesis turned out to be incomplete, when mice nullizygous for p21 waf1/cip1 did not display increased cancer-susceptibilities (Deng et al., 1995) . Accelerated tumor formation and progression after loss of p53 function (Donehower et al., 1992) , therefore, might be explained by the plethora of transcriptional transactivating or repressing activities leading to growth suppression, by the pathways leading to apoptosis, and/or by the regulation of repair activities, such as recombinational repair of double strand breaks. In this work, we provide evidence that transcriptional enhancement and recombination control represent two independent functions of the p53 molecule. Beyond a partial juxtaposition of domains participating in both activities, namely DNA-binding via the core and regulation via the C-terminal end (Cho et al., 1994; Jayaraman and Prives, 1995; Lee et al., 1995; Bayle et al., 1995; Reed et al., 1995; Selivanova et al., 1996) , we also discovered dierences ( Figure 5 ). The loss of the helical tetramerization domain in p53(1 ± 333)her is absolutely detrimental to the binding of 3-stranded junctions and the inhibition of DNA exchange. However, in agreement with observations by others (Shaulian et al., 1993; Subler et al., 1994; Stenger et al., 1994; Pellegata et al., 1995; Tarunina et al., 1996; Ishioka et al., 1997) , p53(1 ± 333)her remained partially active in our plasmid-based transcriptional assays. The lack of a signi®cant growth suppression in response to p53(1 ± 333)her-induction is consistent with earlier observations by Tarunina and colleagues (Tarunina et al., 1996) describing the inability of monomeric p53(1 ± 333)her to transactivate the chromosomally located p21 gene. p53(273H) has been an interesting cancer-related protein, as it transactivates a reporter gene placed downstream of the p53-consensus and suppresses cell growth, (Park et al., 1994; Hachiya et al., 1994; Kawamura et al., 1996; Prasad and Church, 1997) , but is incapable to perform 3'?5' exonuclease activity (Mummenbrauer et al., 1996) . According to our data, p53(273H) serves to distinguish transcriptional activation and better growth control from regulatory functions in recombination. Ectopic production of HDM2, which represents a general inhibitor of p53's growth-related functions by concealing the N-terminal transactivation domain (for review see Prives, 1998) , resulted in downregulation of p53her-dependent transcriptional transactivation. To the contrary, we measured only a minor eect of HDM2 on the inhibition of homologous DNA exchange processes, as was expected from the fact that p53's N-terminus does not participate in binding to 3-stranded junctions.
From the prominent role p53 plays in inducing apoptosis during cellular stress situations, the question might be asked if the apparent inhibition of recombination processes by p53 simply is the consequence of the apoptotic elimination of cells undergoing recombination. We consider this an unlikely possibility. First of all, recombination rates in our SV40 based system are calculated from the ratio of wild-type virus particle production stemming from genetic reconstitution versus ampli®cation. This procedure mathematically eliminates eects resulting from dierences in cell numbers or related to the capacities for virus ampli®cation in response to the p53 status created. Secondly, the fraction of cells with sub-G1 DNA content, according to FACS analysis (data not shown), was negligibly low for all the transgenic LLC-MK 2 cell lines established during the estradiol-induction periods.
Beyond structural, also quantitative aspects served to distinguish functions in transcriptional transactivation and growth control from those in recombination inhibition. As might be predicted from the sensitive response of p53 to only a few DNA double strand breaks, we measured anities for recombination junctions in the range of 10 10 ± 10 11 , whereas weaker binding anities of about 10 8 (Balagurumoorthy et al., 1995) were reported for binding to the consensussequences. The latter might be compensated by the abundance of natural sites and the accumulation of active p53 following stress-induced modi®cation cascades. From recent studies it was postulated that the increased p53 levels after phosphorylation by the damage sensing kinase Atm serve primarily to direct cell-cycle checkpoint functions via sustained regulation of transcription, but are dispensable for the induction of apoptosis and non-speci®c DNA-binding at sites of DNA-damage (Barlow et al., 1997; Wu et al., 1997) . We did not observe a correlation between p53her expression levels and recombination rates, and even small amounts of active p53her protein before estradiol addition were inhibitory. In contrast, transcriptional stimulation by p53her proteins was dependent on the inducing agent and therefore dose sensitive. From these quantitative considerations and from our structurefunction analyses, it seems unlikely that transcriptional transactivation leading to growth suppression and recombination inhibition represent immediately linked regulatory processes. Therefore, surveillance of DNA exchange processes by wild-type p53, which directly leads to genomic stabilization, conceivably represents an independent mechanism inhibiting progression of oncogenic transformation.
Materials and methods
DNA-cloning procedures
Using the polymerase chain reaction (PCR), we constructed pSV53 1 ± 363 her and pSV53 1 ± 333 her to express p53her fusion proteins shortened at the C-terminus. PCR ampli®cation relied on pSV53her-template sequences (Roemer and Friedman, 1993) , the primer 5'-AGGAGGTCTAGAGCCAC-CGTCCAGGGAG-3', and either 5'-CAGATGGATCCC-CCCTGCTCCCCCCTGGCTCCT-3' for the 363-deletion, or 5'-CAGATGGATCCCCACGGATCTGAAGGGTGAA-ATATTCT-3' for the 333-deletion. Bsu36I and BamHI digested PCR-subfragments were inserted into the pSV53her expression vector and veri®ed by sequencing. pSV53(273H)her was created by transferring the Bsu36I-StuI fragment encompassing the correspondingly mutated region from the vector pC53-4.2N 3 into pSV53her. For estradiol-inducible expression of HDM2 pGC-HDM2 was constructed by subcloning the coding region of HDM2 as a Klenow-blunted BamHI-fragment from pCmdmd2 (Roemer and Friedman, 1993) into the EcoRV-restriction site within pMVGalERVP/pGC (Braselmann et al., 1993) . DNAmodifying enzymes were purchased from Boehringer Mannheim, New England Biolabs, Fermentas or Pharmacia.
Establishment and cell culture of transgenic rhesus monkey cell lines LLC-MK 2 [p53(1 ± 363)her], LLC-MK 2 [p53(1 ± 333)her], and LLC-MK 2 [p53(273H)her] cells were established after calcium phosphate mediated co-transfection of LLC-MK 2 cells with in vitro mutagenized variants of pSV53her (10 mg) and phyg (1 mg), LLC-MK 2 (hyg) after transfection with phyg only. p53her mutant expressing clones from 3 ± 5 separate transfections were identi®ed by Western analysis of total homogenates. 14% of the clones selected after pSV53(273H)her/phyg co-transfection, two thirds of the clones obtained with pSV53(1 ± 363)her, and one clone among 43 obtained with pSV53(1 ± 333)her showed expression of the respective p53 mutants. Due to toxic eects we observed after constitutive HDM2 expression via pCmdm2 (Roemer and Friedman, 1993) in both TC7 (wild-type p53) and LLC-MK 2 (mutant p53) cells, we established cell lines conditionally expressing HDM2. For that purpose, LMV cells, which represent LLC-MK 2 cells stably expressing the Gal4-chimera, GalER-VP16 (Braselmann et al., 1993) , were isolated after calcium phosphate mediated precipitation with 20 mg plasmid pMV-7, and tested in transient CAT-reporter assays after GalER-VP16 activation by 2 mM estradiol. Clone LMV-6 was chosen for triple-transfection with 8 mg of the Gal4-promotor-target pGC-HDM2, 8 mg pSV53her (Roemer and Friedman, 1993) , and 2 mg of the plasmid phyg. Picked clones were analysed for estradiol-inducible HDM2 expression via immunoprecipitation followed by immunodetection on Western blots. HDM2-positive clones were subsequently tested for constitutive p53her expression. We obtained 4 coexpressors for both p53her and HDM2 out of 11 clones.
CV1 and TC7 green monkey cells and LLC-MK 2 rhesus monkey cells, were raised as described (WiesmuÈ ller et al., 1996) . LLC-MK 2 (p53her), LLC-MK 2 (neo) and newly established transgenic clones originating from the parental cell line LLC-MK 2 were grown as in DudenhoÈ er et al. (1998) . Antibiotic selection was achieved by the addition of 0.2 mg/ ml Hygromycin B (Boehringer Mannheim). To determine the rate of cell growth, 2610 5 cells were seeded per 60-mm plate with or without b-estradiol (5 mM). Cells from two independent plates were trypsinized and cell numbers counted in a Neubauer chamber on 7 successive days.
SV40 virus generation and recombination assays
SV40 virus generation from recombinant viral DNAs (strain 776 and derivatives), virus infection and determination of virus yields (MOI) via T-Ag immuno¯uorescence were performed exactly as described in WiesmuÈ ller et al. (1996) . Recombination assays were executed and evaluated by plaque assays accordingly (WiesmuÈ ller et al., 1996) , except that bestradiol (Sigma) containing medium was added to LLC-MK 2 (p53her) and LLC-MK 2 (neo) cells immediately after virus infection. A single recombination rate determination (n=1) used to calculate mean values and standard deviations from several determinations resembles the average value from 4 ± 6 independent co-infections each.
Preparation of total homogenates and nuclear extracts from monkey cells
Total cellular homogenates were harvested by a rubber policeman from subcon¯uent cultures 24 h after seeding 5610 5 cells per 90-mm plate.
For the preparation of nuclear extracts cells were collected from 30 ± 90-mm plates. Resuspension and extraction steps using 1.5 ml buer each were following the protocol developed by Thierry Soussi, University P et M Curie Paris, which we described for insect cells in DudenhoÈ er et al. (1998) .
Cell lysis, immunoprecipitation, SDS ± PAGE and Western blot analysis
After growth for 4 h in the presence or absence of 2 mM bestradiol subcon¯uent cultures of individual LLC-MK 2 (p53her)-, LMV(HDM2/p53her)-, or control LMV6-clones were extracted and immunoprecipitations performed with polyclonal serum from guinea-pig directed towards HDM2 exactly as described (Henning et al., 1997) .
For Western analysis proteins on SDS-polyacrylamide gels were transferred to a PVDF membrane (Immobilon-P, Millipore). p53 and HDM2 were immunodetected by specific primary antibodies coupled to recognition by horseradish peroxidase-conjugated secondary sera, and visualization by chemiluminescence enhancement according to the ECLprotocol (Pierce). Relative protein amounts were quanti®ed after scanning autoradiographs by computer-assisted analysis using the Tina 2.0 program.
Transient transfections and determination of transcriptional transactivation activities
To demonstrate transcriptional transactivation by p53her variants LLC-MK 2 -and LMV-derived cells were transiently transfected with the p53-reporter plasmid pG13-CAT (Kern et al., 1992) by use of FuGENE TM (Boehringer Mannheim). After a recovery phase of 16 h the cells from one culture dish each were split, subjected to another recovery phase of 8 h, and further cultivated for 16 h in the presence or absence of 2 mM b-estradiol. Subsequently, cell extracts were prepared and chloramphenicol acetyltransferase (CAT) quanti®ed with the help of the CAT-ELISA kit (Boehringer Mannheim). For the determination of speci®c transcriptional transactivation activities we measured protein concentrations by use of the BCA protein assay reagent (Pierce GmbH).
EMSA analysis with p53 puri®ed from insect cells
High Five
TM insect cells (Invitrogen) were infected either with recombinant baculovirus directing the expression of Nterminally histidine-tagged murine wild-type p53 , histidine-tagged shortened versions of murine p53, of untagged human wild-type p53, or of human mutant proteins p53(273P) and p53(248P). p53 from human origin was highly enriched from nuclear extracts, exactly as described in DudenhoÈ er et al. (1998) , or puri®ed by immunoanity chromatography employing the monoclonal antibody Pab421, as described in Mummenbrauer et al. (1996) . Murine p53 proteins from insect cells were independently puri®ed to homogeneity via anity binding of the N-terminal tag consisting of 6 histidines to talon TM metal resin from Clontech (Mummenbrauer et al., 1996) , stored at 48C and applied to band-shift analyses using 3-stranded substrates within 2 days. The quality of wild-type p53 protein preparations was checked by exonuclease activity measurements and gel mobility shift assays with doublestranded oligos covering the wild-type p53-speci®c RGC-site (Kern et al., 1992) . To demonstrate intact binding activities for mutant p53 preparations, EMSAs with DNA-fragments corresponding to the mutant p53-speci®c MAR/SARelements were performed . Protease inhibitors were purchased from Bayer, Biomol or Serva.
Puri®ed proteins were employed for band-shift analyses using 3-stranded DNA substrates representing the recombination intermediate at the SV40-tsVP1(286S) locus. Perfectly matching and A-G mismatch substrates were produced as described in DudenhoÈ er et al. (1998) . For gel shift analyses 32 P-labeled DNA junctions were added to the mixtures to result in a constant concentration of 30 pM, or in varying DNA substrate concentrations for anity measurements. p53 proteins were included at the concentrations individually indicated. Band intensities were quanti®ed by Phosphorimager analysis, and apparent equilibrium dissociation constants, K D , were calculated from Scatchard plots (DudenhoÈ er et al., 1998) .
